AVGR Avinger Inc

Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019

Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019

REDWOOD CITY, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2019 after the close of trading on Wednesday, July 31, 2019. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Individuals interested in listening to the conference call may do so by dialing 844-407-9500 for domestic callers or for international callers. To listen to a live webcast, please visit and select Investor Relations.

A replay of the call will be available beginning August 8, 2019 at approximately 7:30pm PT/10:30pm ET through August 15, 2019. To access the replay, dial 919-882-2331 and reference Conference ID: 51715. The webcast will also be available on Avinger's website following completion of the call at .

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit .

Investor Contact:

Mark Weinswig

Chief Financial Officer

Avinger, Inc.

(650) 241-7916

Matt Kreps

Darrow Associates Investor Relations

(214) 597-8200

EN
26/07/2019

Underlying

AVGRAvinger Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avinger Inc

 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Reports Third Quarter 2019 Financial Results

Avinger Reports Third Quarter 2019 Financial Results Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended September 30, 2019. Third Quarter Highlights Increased revenue 19% year-...

November 5, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Closes $4.5 Million Equity Offering

Avinger Closes $4.5 Million Equity Offering REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to ...

August 26, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Prices $4.5 Million Underwritten Public Offering of Common Sto...

Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Comp...

August 22, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Announces Proposed Underwritten Public Offering of Common Stoc...

Avinger Announces Proposed Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to ...

August 21, 2019 1 EN
 PRESS RELEASE
Free
AVGR AVINGER INC

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019 Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Increased revenue 26% from the first quart...

July 31, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch